AAP
STLN

Arax Advisory Partners’s Starling Oncology STLN Stock Holding History

Arax Advisory Partners’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$159K Buy
29,213
+507
+2% +$2.13K ﹤0.01% 2410
2026
Q1 		$88.1K Buy
+28,706
New +$88K ﹤0.01% 1452
2025
Q4 		– Sell
-14
Closed -$49 – 4524
2025
Q3 		$49 Buy
+14
New +$48 ﹤0.01% 3534

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Arax Advisory Partners's STLN Position: Q2 2026 in Review

Arax Advisory Partners increased its Starling Oncology (STLN) stake by 1.8% in Q2 2026, buying an estimated $2.13K and bringing the position to 29,213 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #2410.

Arax Advisory Partners first reported a position in STLN in Q3 2025 and has held it in 3 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Arax Advisory Partners held 29,213 shares of Starling Oncology worth $159K as of Q2 2026.
  • Arax Advisory Partners bought 507 Starling Oncology shares in Q2 2026, an estimated $2.13K.
  • Starling Oncology made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2410 holding.
  • Arax Advisory Partners first reported a position in Starling Oncology in Q3 2025 and has held it in 3 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.